Literature DB >> 1401155

Efficacy of MMPI-2 validity scales and MCMI-II modifier scales for detecting spurious PTSD claims: F, F-K, Fake Bad Scale, ego strength, subtle-obvious subscales, DIS, and DEB.

P R Lees-Haley.   

Abstract

This study compared 119 personal injury claimants' scores on MMPI-2 and MCMI-II malingering scales. Data from 55 pseudo-PTSD patients and 64 controls confirm the utility of the scales examined. The following cut-offs were most effective for identifying spurious PTSD: F greater than 62, F-K = greater than -4, Es = greater than 30, FBS = greater than 24 (men), FBS = greater than 26 (women), total obvious minus subtle = greater than 90, DIS = greater than 60, and DEB = greater than 60. Pseudo-PTSD patients were those who (1) claimed to be suffering a psychological injury (2) that was so severe that it was disabling (3) due to an experience that was entirely implausible as a candidate for PTSD criterion A in DSM-III-R and (4) scored T = 65 or higher on both PK and PS, the post-traumatic stress disorder subscales of the MMPI-2.

Entities:  

Mesh:

Year:  1992        PMID: 1401155     DOI: 10.1002/1097-4679(199209)48:5<681::aid-jclp2270480516>3.0.co;2-q

Source DB:  PubMed          Journal:  J Clin Psychol        ISSN: 0021-9762


  3 in total

Review 1.  Practical guidelines in the use of symptom validity and other psychological tests to measure malingering and symptom exaggeration in traumatic brain injury cases.

Authors:  L M Etcoff; K M Kampfer
Journal:  Neuropsychol Rev       Date:  1996-12       Impact factor: 7.444

Review 2.  Multimodal approach to identifying malingered posttraumatic stress disorder: a review.

Authors:  Shahid Ali; Shagufta Jabeen; Farzana Alam
Journal:  Innov Clin Neurosci       Date:  2015 Jan-Feb

3.  The impact of NEO PI-R gender norms on the assessment of personality disorder profiles.

Authors:  Douglas B Samuel; Emily B Ansell; Christopher J Hopwood; Leslie C Morey; John C Markowitz; Andrew E Skodol; Carlos M Grilo
Journal:  Psychol Assess       Date:  2010-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.